Zhejiang Cheng Yi Pharmaceutical (603811.SH) subsidiary Fujian Huakang obtained drug GMP compliance inspection results.

Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that recently, its subsidiary Fujian Huakang Pharmaceutical Co., Ltd. (hereinafter referred to as "Fujian Huakang") learned from the website of the Fujian Provincial Medical Products Administration the drug GMP compliance inspection results (No.: FJSC2026-038). The production and quality management of the company's active pharmaceutical ingredient glucosamine hydrochloride (newly added production line for glucosamine hydrochloride API in Workshop B09) comply with the requirements of the Good Manufacturing Practice for Drugs (2010 Revision) and its appendices. The obtaining of the above drug GMP compliance inspection results by Fujian Huakang this time indicates that the relevant production lines of Fujian Huakang comply with GMP requirements, which is conducive to Fujian Huakang's continued assurance of product quality and sustained and stable production capacity, better meeting market demand, and will have a positive effect on the company's future development.